耐藥基因产物及CerbB-2ki-67在胃癌中的表达23.docVIP

多药耐药基因产物及CerbB-2、ki-67在 胃癌中的表达及其临床病理学意义 韩军平1、2 刘斌1、2 孟晓燕3 杨艳丽1 苏勤军1 Study the expressions of Pg-p，GST-π，Topo-II , cancer gene CerbB-2, cell multiplication index ki-67 and the clinical pathology significance in the stomach cancer organizes HAN Jun-ping1、2 ,LIU Bin1、2 ,MENG Xiao-yan3,YANG Yan-li1 ,SU Qin-Jun1 1 Department of Pathology, Lanzhou General Hospital of Lanzhou Military Area Command of Chinese PLA, Lanzhou730050, Gansu Province, China.2 Institute of Pathology, College of Basic Medical Science, Lanzhou University, Lanzhou730030，Gansu Province, China; 3 First Peoples Hospital in Baiyin City 730900, China. [abstract]: ObJective To investigate the expressions of Pg-p，GST-π，Topo-II , cancer gene CerbB-2, cell multiplication index ki-67 and the clinical pathology significance in the stomach cancer; Method Their expression was examined by immunohistorchemistry stain. Result No remarkable difference in the positive expressions of Pgp、GST-π were found with stomach cancers auren divides, the pathology graduation and the lymph node metastasis (P0．05)，but the depth of the cancer infiltration has the significance difference (P0．05)．No remarkable difference in the positive expressions of Topo-II were found with the stomach tumor differentiation, and the lymph node (P0.05)，but the stomach cancers auren divides has the significance difference (P0．05). No remarkable difference in the positive expressions of CerbB-2, ki-67 were found with stomach cancers auren divides, the pathology graduation and the depth of the cancer infiltration (P0.05)，but the lymph node has the significance difference (P0.05). Conclusion There are great meanings to judge the stomach cancer patient prognosis and the instruction clinical individuation treatment by union examination on Pgp, Topo-II and GST-π as well as CerbB-2 and ki-67 . Key words：Multidrug resistance Gene；CerbB-2；ki-67；Gastric carcinoma [摘要]： 目的 探讨多药耐药基因产物Pgp、GST-π、Topo-II、CerbB-2和细胞增殖指数ki-67在胃癌组织中的表达及其临床病理学意义。 方法 用免疫组织化学染色SP法检